Cargando…

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

BACKGROUND: A population pharmacokinetic model was developed to characterize mecillinam (MEC) pharmacokinetics (PK) and urine exposure after intravenous (IV) administration of MEC or after oral (PO) administration of its prodrug pivmecillinam (PIV) in healthy subjects and patients with renal impairm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santerre Henriksen, Anne Laurence, Lagraauw, Maxime, Prohn, Marita, Lindbom, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751708/ http://dx.doi.org/10.1093/ofid/ofac492.674

Ejemplares similares

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales
por: Lodise, Thomas P, et al.
Publicado: (2021)

Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial
por: Vik, Ingvild, et al.
Publicado: (2018)

Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus—Cumulative Observational Data from Four Recent Clinical Studies
por: Jansåker, Filip, et al.
Publicado: (2019)

Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men
por: Montelin, Hanna, et al.
Publicado: (2019)

Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial()
por: Jansåker, Filip, et al.
Publicado: (2019)

Retracted: In vivo mecillinam resistance in Escherichia coli after pivmecillinam treatment of a urinary tract infection
Publicado: (2019)

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
por: Henriksen, Anne Santerre, et al.
Publicado: (2021)

The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol
por: Jansåker, Filip, et al.
Publicado: (2016)

Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study
por: Jansåker, Filip, et al.
Publicado: (2019)

Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI)
por: Tverring, Jonas, et al.
Publicado: (2023)

Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland
por: O’Kelly, Fardod, et al.
Publicado: (2016)

1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections
por: Katsube, Takayuki, et al.
Publicado: (2020)

The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study
por: Hansen, Bjørn Åsheim, et al.
Publicado: (2022)

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019
por: Hawser, Stephen, et al.
Publicado: (2021)

Psychosocial burden of recurrent uncomplicated urinary tract infections
por: Naber, Kurt G., et al.
Publicado: (2022)

Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19
por: Piwowarczyk, Paweł, et al.
Publicado: (2023)

Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers
por: Edwina, Angela Elma, et al.
Publicado: (2023)

Predictors of Symptom Duration and Bacteriuria in Uncomplicated Urinary Tract Infection
por: Bollestad, Marianne, et al.
Publicado: (2018)

Recurrent uncomplicated urinary tract infections: definitions and risk factors
por: Cai, Tommaso
Publicado: (2021)

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)
por: Overcash, J. Scott, et al.
Publicado: (2020)

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018
por: Hawser, Stephen, et al.
Publicado: (2020)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis
por: Sidamo, Temesgen, et al.
Publicado: (2022)

Optimizing the diagnostic work-up of acute uncomplicated urinary tract infections
por: Knottnerus, Bart J, et al.
Publicado: (2008)

Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects
por: Wiedemann, Bernd, et al.
Publicado: (2014)

Adherence to International Guidelines for the Treatment of Uncomplicated Urinary Tract Infections in Lebanon
por: Kabbara, Wissam K., et al.
Publicado: (2018)

Whole-Person, Urobiome-Centric Therapy for Uncomplicated Urinary Tract Infection
por: Garofalo, Luciano, et al.
Publicado: (2022)

Antibiotic treatment failure of uncomplicated urinary tract infections in primary care
por: Koh, Sky Wei Chee, et al.
Publicado: (2023)

Population Pharmacokinetic–Pharmacodynamic Modeling and Probability of Target Attainment Analysis of Rocuronium and Sugammadex in Children Undergoing Surgery
por: Grześkowiak, Małgorzata, et al.
Publicado: (2022)

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches
por: Khalid, Kashaf, et al.
Publicado: (2023)

¡MS-DOS 6.22 fácil!
por: Fulton, Jennifer
Publicado: (1994)

MCITP 70-622 exam cram
por: Mancuso, Paul, et al.
Publicado: (2008)

Using MS-DOS 6.22
por: Cooper, Jim
Publicado: (2002)

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe
por: McQuiston Haslund, Josephine, et al.
Publicado: (2013)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Clarinet concerto, K. 622 Sinfonia concertante, K. 364 /
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_9fc1labhsr03uq5spf1teqklg9